Biogen Inc   (BIIB)
Other Ticker:  
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare

Biogen Inc 's



BIIB Sales vs. its Competitors Q4 2020

Comparing the results to its competitors, Biogen Inc reported Total Revenue decrease in the 4 quarter 2020 year on year by -22.3 %, despite revenue increase by most of its competitors of 7.4 %, recorded in the same quarter.

List of BIIB Competitors

With net margin of 12.53 % company achieved higher profitability than its competitors.

More on BIIB Margin Comparisons

Revenue Growth Comparisons

Net Income Comparison

Biogen Inc Net Income in 4 quarter 2020 declined year on year by -75.17 %, faster than the decline experianced by the competitors

<<  More on BIIB Income Comparisons

Biogen Inc 's Comment on Competitors and Industry Peers

Competition in the biotechnology and pharmaceutical industries is intense and comes from many and varied sources, including specialized biotechnology firms and large pharmaceutical companies. Many of our competitors are working to develop products similar to those we are developing or already market and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. Certain of these companies have substantially greater financial, marketing and research and development resources than we do.
We believe that competition and leadership in the industry is based on managerial and technological excellence and innovation as well as establishing patent and other proprietary positions through research and development. The achievement of a leadership position also depends largely upon our ability to identify and exploit commercially the products resulting from research and the availability of adequate financial resources to fund facilities, equipment, personnel, clinical testing, manufacturing and marketing. Another key aspect of remaining competitive within the industry is recruiting and retaining qualified scientists and technicians. We believe that we have been successful in attracting skilled and experienced scientific personnel.
Competition among products approved for sale may be based, among other things, on patent position, product efficacy, safety, convenience, reliability, availability and price. In addition, early entry of a new pharmaceutical product into the market may have important advantages in gaining product acceptance and market share. Accordingly, the relative speed with which we can develop products, complete the testing and approval process and supply commercial quantities of products will have an important impact on our competitive position.

We may face increased competitive pressures as a result of the emergence of biosimilars. In the U.S., a number of our marketed products, including AVONEX, TYSABRI and RITUXAN, are licensed under the Public Health Service Act (PHSA) as biological products. In March 2010, U.S. healthcare reform legislation amended the PHSA to authorize the FDA to approve biological products, known as biosimilars or follow-on biologics, that are shown to be highly similar to previously approved biological products based upon potentially abbreviated data packages. The approval pathway for biosimilars does, however, grant a biologics manufacturer a 12 year period of exclusivity from the date of approval of its biological product before biosimilar competition can be introduced. Biosimilars legislation has also been in place in the E.U. since 2003. In December 2012, guidelines issued by the EMA for approving biosimilars of marketed monoclonal antibody products became effective. If a biosimilar version of one of our products were approved, it could reduce our sales of that product.
Additional information about the competition that our marketed products face is set forth below.
Each of AVONEX, TYSABRI and TECFIDERA competes with the following products:

Along with us, a number of companies are working to develop additional treatments for MS that may in the future compete with AVONEX, TYSABRI, TECFIDERA or all of them. For example, a marketing application for LEMTRADA (alemtuzumab) (developed by Sanofi) has been approved in the E.U. as a treatment for MS in September 2013. In addition, the commercialization of our own products, such as TECFIDERA, may negatively impact future sales of AVONEX, TYSABRI or both. Further, following the expected expiration of Teva Pharmaceutical’s patent protection for COPAXONE (May 2014 for its U.S. patents and in May 2015 for its European patents), we anticipate that additional companies will introduce similar versions of COPAXONE that may also create further competition in the MS market.

FAMPYRA is indicated as a treatment to improve walking in adult patients with MS who have walking disability and is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS. FAMPYRA is currently the only therapy approved to improve walking in patients with MS, and benefits from exclusivity rights that prohibit generic versions from being marketed.

FUMADERM competes with several different types of therapies in the psoriasis market within Germany, including oral systemics such as methotrexate and cyclosporine.
RITUXAN competes with several different types of therapies in the oncology market, including:

TREANDA (bendamustine HCL) (marketed by Cephalon (Teva Pharmaceuticals)), which is indicated for CLL and for patients with indolent B-cell NHL that has progressed within 6 months of treatment with RITUXAN.

ARZERRA (ofatumumab) (marketed by GenMab in collaboration with GlaxoSmithKline), which is indicated for CLL patients refractory to both alemtuzumab and fludarabine.

We also expect that over time GAZYVA will compete with RITUXAN, TREANDA AND ARZERRA in the oncology market. In addition, we are aware of other anti-CD20 molecules, including biosimilars, in development that, if successfully developed and registered, may compete with RITUXAN and GAZYVA in the oncology market.
RITUXAN competes with several different types of therapies in the RA market, including:

Traditional therapies for RA, including disease-modifying anti-rheumatic drugs such as steroids, methotrexate and cyclosporine, and pain relievers such as acetaminophen.

TNF inhibitors, such as REMICADE (infliximab) and SIMPONI and SIMPONI ARIA (golimumab) (marketed by Johnson & Johnson), HUMIRA (adalimumab) (marketed by AbbVie, Inc.), ENBREL (etanercept) (marketed by Amgen, Inc. and Pfizer) and CIMZIA (certolizumab pegol) (marketed by UCB, S.A.).

ORENCIA (abatacept) (marketed by Bristol-Myers Squibb Company).

ACTEMRA (tocilizumab) (marketed by the Roche Group).

XELJANZ (tofacitinib) (marketed by Pfizer).
We are also aware of other products, including biosimilars, in development that, if successfully developed and registered, may compete with RITUXAN in the RA market.


Overall company Market Share Q4 2020

Overall company, revenue fell by -22.3 % and company lost market share, to approximate 2.64 %.

<<  More on BIIB Market Share.

*Market share calculated with total revenue.

BIIB's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

Biogen Inc 13,445 41,056 4,061 7,550
Allergan plc 16,096 64,063 -2,479 10,500
Pfizer Inc 41,908 194,467 9,652 78,300
Wyeth 0 0 0 0
Amgen Inc 32,341 131,005 7,264 17,900
Covidien Plc 10,880 0 1,605 39,500
Bristol Myers Squibb Co 42,518 142,778 -8,995 25,000
Merck and Co Inc 47,994 186,023 7,082 70,000
Abbott Laboratories 34,608 213,503 4,495 77,000
Johnson and Johnson 82,584 418,201 14,714 126,500
Abbvie inc 45,804 190,709 4,622 26,000
Celgene Corp 16,982 78,961 1,834 6,012
Baxter International Inc 11,673 0 1,110 0
SUBTOTAL 396,833 1,660,767 44,965 484,262


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

LAMR's Profile

Stock Price

LAMR's Financials

Business Description


Charts & Quotes

LAMR's News


LAMR's Competitors

Customers & Markets

Economic Indicators

LAMR's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries





At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071